TransCode Therapeutics Presents Phase 1a Clinical Data for TTX-MC138 at ESMO Congress 2026
PR Newswire•26/10/2026•07:31 ET
1
Key Highlights
- ➤TTX-MC138 Phase 1a met its primary safety endpoint, with no dose-limiting toxicities observed
- ➤TTX-MC138 showed disease stabilization and extended progression-free intervals in some patients
- ➤TTX-MC138 was evaluated across four dose levels ranging from 0.8 mg/kg to 4.8 mg/kg
- ➤Dose-dependent plasma exposure was observed across all four evaluated dose levels
- ➤TTX-MC138 is currently being evaluated in a Phase 2a trial under the PRE-I-SPY program
Expert Statements
Dan Vlock, MD, Consulting Senior Medical Advisor of TransCode Therapeutics
“These data provide additional insight into the safety, clinical activity and durability findings observed in the Phase 1a study.”
Dan Vlock, MD, Consulting Senior Medical Advisor of TransCode Therapeutics
“The disease stabilization observed across this heavily pretreated and heterogeneous patient population, together with the extended progression-free intervals seen in a subset of patients, supports the continued clinical evaluation of TTX-MC138.”
TransCode Therapeutics Presents Phase 1a Clinical Data for TTX-MC138 at ESMO Congress 2026 PR Newswire
Poster highlights durable disease control, acceptable tolerability and exploratory evidence of treatment-associated antitumor immune activity in patients with advanced solid tumors
Get started
Create a free account to read the full story.